Reporting of adjuvant breast cancer trials: when is the right time?
- PMID: 22105825
- PMCID: PMC3255558
- DOI: 10.1200/JCO.2011.38.2747
Reporting of adjuvant breast cancer trials: when is the right time?
Comment on
-
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.J Clin Oncol. 2012 Jan 1;30(1):11-8. doi: 10.1200/JCO.2011.35.4639. Epub 2011 Nov 21. J Clin Oncol. 2012. PMID: 22105826 Clinical Trial.
References
-
- Joensuu H, Kellokumpu-Lehtinen P-L, Huovinen R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial. J Clin Oncol. 2012;30:11–18. - PubMed
-
- Joensuu H, Kellokumpu-Lehtinen P, Huovinen R, et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): Efficacy in patients with triple-negative breast cancer (BC) J Clin Oncol. 2010;28(suppl 15; abstr 531):75s.
-
- Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: An open-label, randomised controlled trial. Lancet Oncol. 2009;10:1145–1151. - PubMed
-
- Poole CJ, Earl HM, Hiller L, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355:1851–1862. - PubMed
-
- Earl HM, Vallier A, Hiller L, et al. Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR) J Clin Oncol. 2009;27(suppl 15; abstr 522):12s.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical